Speaker: Aleksandar Danilovski, Chief Scientific Officer, Xellia Pharmaceuticals (Denmark)
Moderator: Michael Scholl, Chief Executive Officer, Leukocare AG (Germany)
Aleksandar’s presentation discussed:
- Are CMC and formulation efforts treated as the foster child in the innovation and development armament?
- Underestimating CMC and formulation aspects can potentially cause significant delays and project failures
- Appropriate (what, how and when) CMC and formulation innovation and development strategies can improve overall probability of project success, can bring competitive advantages (including IP umbrella) and can reduce time to market
- Do it right the first time!
This live webinar including interactive Q&A session was broadcast on 29 April 2021.
If you have questions or comments, please let us know: email@example.com.